Ananda Pharma Advances MRX1 Trial for Chemotherapy Side Effects

The investigational product is now held at the university's central pharmacy, with staff currently screening participants for the first dosing. This double-blind, placebo-controlled study will enroll 92 patients to evaluate the safety and efficacy of the oral solution. Funding for the research is provided by the National Institute for Health and Care Research, with Professor Marie Fallon leading the clinical design.

CIPN represents a critical gap in oncology care, often forcing doctors to reduce or halt chemotherapy, which elevates patient mortality risks. With over 400,000 new cases annually in the US alone—costing the healthcare system roughly $2.5 billion—the trial aims to measure both symptom relief and broader impacts on patient quality of life. Ananda Pharma CEO Melissa Sturgess cited Fallon’s expertise as a key factor in the trial's rigorous design, following the company's successful completion of initial human safety studies earlier this year.